fda warning letters glp-1 compounding october 2025 Report: FDA must enforce rules on compounded GLP-1s

FDA issued 30 warning letters to telehealth companies for false and misleading claims about compounded GLP-1 products. This marks the second round of enforcement action since the agency's September crackdown on misleading

27.82

★★★★☆4.8 (126)

FDA is moving to restrict mass-marketed compounded GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified

25.09

★★★★★4.9 (98)

Why the FDA Issued 30 Warning Letters to Telehealth Sites Marketing Compounded GLP-1s

27.50

★★★★★5.0 (157)

September 15, 2025: Telehealth company must stop implying its compounded GLP -1 is FDA-approved, warns FDA – Partnership for Safe Medicines

26.07

★★★★★4.7 (84)

National

29.31

★★★★★4.9 (203)

Today, the FDA established a “green list” import alert to help stop potentially dangerous GLP-1 active pharmaceutical ingredients from unverified foreign sources from entering the U.S. market. The agency will continue to

25.63

★★★★★5.0 (176)

FDA Targets GLP-1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling

25.59

★★★★★4.8 (132)